Compare LBTYK & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBTYK | ACAD |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | N/A | 2000 |
| Metric | LBTYK | ACAD |
|---|---|---|
| Price | $11.23 | $22.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $30.55 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 02-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $15.41 | $18.80 |
| Revenue Next Year | $3.03 | $11.70 |
| P/E Ratio | ★ N/A | $9.71 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $9.21 | $14.18 |
| 52 Week High | $13.12 | $28.35 |
| Indicator | LBTYK | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 56.45 |
| Support Level | $10.59 | $19.87 |
| Resistance Level | $11.51 | $22.97 |
| Average True Range (ATR) | 0.33 | 0.65 |
| MACD | -0.09 | 0.11 |
| Stochastic Oscillator | 6.40 | 97.81 |
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.